Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 14, 2018

SELL
$16.19 - $20.3 $191,058 - $239,560
-11,801 Closed
0 $0
Q3 2017

Nov 14, 2017

SELL
$15.52 - $18.94 $208,681 - $254,667
-13,446 Reduced 53.26%
11,801 $218,000
Q2 2017

Aug 14, 2017

BUY
N/A
25,247
25,247 $442,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Highbridge Capital Management LLC Portfolio

Follow Highbridge Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Highbridge Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Highbridge Capital Management LLC with notifications on news.